生命科学资讯

Agilent Technologies, Inc. $A Shares Sold by Primecap Management Co. CA - MarketBeat

Goldman Sachs Adjusts Price Target on Agilent Technologies to $150 From $170, Maintains Buy Rating - marketscreener.com

Thermo Fisher unveils test to aid in dosing of antirejection drug - Fierce Biotech

Erste Asset Management GmbH Trims Stock Position in Thermo Fisher Scientific Inc. $TMO - MarketBeat

Thermo Fisher Scientific Stock To $390? - Trefis

Decoding Thermo Fisher Scientific Inc (TMO): A Strategic SWOT In - GuruFocus

Here’s What Analysts Think About Thermo Fisher Scientific (TMO) Post Earnings - Yahoo Finance

Assessing Illumina (ILMN) Valuation After Recent Share Price Momentum Shifts - simplywall.st

Spatial Biomarker Panels for Clinical Trials

Generate caps a strong month for biotech IPOs with $400M offering

Illumina Launches TruPath Genome, Unveils NovaSeq X Roadmap, and Drives Cancer Breakthroughs with Connected Multiomics - The Korea Herald

As CAR-T cell therapy gains ground on solid tumors, regulatory red tape hinders progress

'Like talking to a brick wall': Senate hearing takes aim at FDA's rare disease review process

Agilent Technologies (A) Margin Slippage Challenges Bullish Earnings Improvement Narrative - simplywall.st